Amit Kumar, Chief Executive Officer and Director of Anixa Biosciences Inc, filed a Form 4 on November 2, 2026, disclosing a purchase of 5,000 shares of common stock on October 30, 2026.

Key Highlights

  • Reporting person: Amit Kumar, serving as Chief Executive Officer and Director of Anixa Biosciences Inc (NASDAQ:ANIX)
  • Transaction: Purchase (transaction code P) of 5,000 shares of common stock on October 30, 2026
  • Price paid: $3.17 per share
  • Beneficial ownership after transaction: 685,000 shares of common stock held directly
  • Filing date: November 2, 2026

Amit Kumar's October 2026 Open-Market Purchase of Anixa Biosciences Common Stock

According to the Form 4 filing, Amit Kumar, who holds dual roles as Chief Executive Officer and Director of Anixa Biosciences Inc, acquired 5,000 shares of the company's common stock on October 30, 2026. The transaction was coded "P," indicating an open-market purchase, at a price of $3.17 per share. The filing reports direct ownership following the transaction.

Following the reported transaction, the filing discloses that Kumar beneficially owned 685,000 shares of Anixa Biosciences common stock directly. No derivative securities transactions were reported in Table II of the filing. The form was signed by Amit Kumar and filed with the SEC on November 2, 2026.

The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox on the form was not checked. The issuer is identified in the filing as Anixa Biosciences Inc, trading on NASDAQ under the symbol ANIX.

What Was Disclosed

Amit Kumar, CEO and Director of Anixa Biosciences Inc (NASDAQ:ANIX), disclosed a purchase of 5,000 shares of common stock at $3.17 per share on October 30, 2026, bringing his directly held beneficial ownership to 685,000 shares.